| Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience AJM Ferreri, JY Blay, M Reni, F Pasini, M Spina, A Ambrosetti, ... Journal of Clinical Oncology 21 (2), 266-272, 2003 | 923 | 2003 |
| Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating … CN Sternberg, PHM De Mulder, JH Schornagel, C Théodore, SD Fossa, ... Journal of Clinical Oncology 19 (10), 2638-2646, 2001 | 678 | 2001 |
| Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours CN Sternberg, P De Mulder, JH Schornagel, C Theodore, SD Fossa, ... European journal of cancer 42 (1), 50-54, 2006 | 580 | 2006 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 569 | 2017 |
| HIV-associated lymphomas and gamma-herpesviruses A Carbone, E Cesarman, M Spina, A Gloghini, TF Schulz Blood, The Journal of the American Society of Hematology 113 (6), 1213-1224, 2009 | 437 | 2009 |
| Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study C Simonelli, M Spina, R Cinelli, R Talamini, R Tedeschi, A Gloghini, ... Journal of Clinical Oncology 21 (21), 3948-3954, 2003 | 322 | 2003 |
| Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma A Santoro, M Magagnoli, M Spina, G Pinotti, L Siracusano, M Michieli, ... haematologica 92 (1), 35-41, 2007 | 295 | 2007 |
| Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials M Spina, U Jaeger, JA Sparano, R Talamini, C Simonelli, M Michieli, ... Blood 105 (5), 1891-1897, 2005 | 237 | 2005 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 231 | 2023 |
| Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients SK Barta, X Xue, D Wang, R Tamari, JY Lee, N Mounier, LD Kaplan, ... Blood, The Journal of the American Society of Hematology 122 (19), 3251-3262, 2013 | 224 | 2013 |
| Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial U Vitolo, A Chiappella, S Franceschetti, AM Carella, I Baldi, G Inghirami, ... The Lancet Oncology 15 (7), 730-737, 2014 | 207 | 2014 |
| Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus … E Vaccher, M Spina, G di Gennaro, R Talamini, G Nasti, O Schioppa, ... Cancer 91 (1), 155-163, 2001 | 206 | 2001 |
| AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy N Mounier, M Spina, J Gabarre, M Raphael, G Rizzardini, JB Golfier, ... Blood 107 (10), 3832-3840, 2006 | 193 | 2006 |
| Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection M Spina, J Gabarre, G Rossi, M Fasan, C Schiantarelli, E Nigra, M Mena, ... Blood, The Journal of the American Society of Hematology 100 (6), 1984-1988, 2002 | 187 | 2002 |
| The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi S Luminari, I Biasoli, L Arcaini, A Versari, C Rusconi, F Merli, M Spina, ... Annals of oncology 24 (8), 2108-2112, 2013 | 183 | 2013 |
| Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma J Dal Col, P Zancai, L Terrin, M Guidoboni, M Ponzoni, A Pavan, M Spina, ... Blood, The Journal of the American Society of Hematology 111 (10), 5142-5151, 2008 | 183 | 2008 |
| Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi L Arcaini, D Vallisa, S Rattotti, VV Ferretti, AJM Ferreri, P Bernuzzi, ... Annals of Oncology 25 (7), 1404-1410, 2014 | 176 | 2014 |
| Temozolomide as salvage treatment in primary brain lymphomas M Reni, F Zaja, W Mason, J Perry, E Mazza, M Spina, R Bordonaro, ... British Journal of Cancer 96 (6), 864-867, 2007 | 175 | 2007 |
| High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral … A Re, C Cattaneo, M Michieli, S Casari, M Spina, M Rupolo, B Allione, ... Journal of Clinical Oncology 21 (23), 4423-4427, 2003 | 169 | 2003 |
| Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter … A Tucci, M Martelli, L Rigacci, P Riccomagno, MG Cabras, F Salvi, ... Leukemia & lymphoma 56 (4), 921-926, 2015 | 164 | 2015 |
